ロード中...
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
BACKGROUND: Doxycycline is often used for treating COVID-19 respiratory symptoms in the community despite an absence of evidence from clinical trials to support its use. We aimed to assess the efficacy of doxycycline to treat suspected COVID-19 in the community among people at high risk of adverse o...
保存先:
| 出版年: | Lancet Respir Med |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier Ltd.
2021
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8315758/ https://ncbi.nlm.nih.gov/pubmed/34329624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-2600(21)00310-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|